Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.
about
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something NewTracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncologyModulatory effect of luteolin on redox homeostasis and inflammatory cytokines in a mouse model of liver cancerTransarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysisAdjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrenceThe role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management.Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant IIIMicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cellsComparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm.Prostate tumor overexpressed 1 is a novel prognostic marker for hepatocellular carcinoma progression and overall patient survival.Synthesis and bio-molecular study of (+)-N-Acetyl-α-amino acid dehydroabietylamine derivative for the selective therapy of hepatocellular carcinomaMicroRNA-9 is a ponderable index for the prognosis of human hepatocellular carcinomaImage-aided Suicide Gene Therapy Utilizing Multifunctional hTERT-targeting Adenovirus for Clinical Translation in Hepatocellular Carcinoma.Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical managementMetronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.MicroRNAs and liver disease: viral hepatitis, liver fibrosis and hepatocellular carcinoma.Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.Serine-arginine protein kinase 1 is associated with hepatocellular carcinoma progression and poor patient survival.Genome-wide identification of differential methylation between primary and recurrent hepatocellular carcinomas.Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma.Long non-coding RNA AB209630 suppresses cell proliferation and metastasis in human hepatocellular carcinoma.Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients.Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research.MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2.Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival
P2860
Q26744542-21DB5008-32BE-4E32-AEB2-732DA812F511Q28085398-B3138133-0BBC-4B2A-AAEB-3C7FC16857ABQ28468620-C750EE07-0F0B-44BB-98DD-682C7651A844Q33710153-4A97530F-AAE9-4CE2-8D13-67910388BB99Q34093919-C30C23E6-6CF2-40E6-AB99-C0E7315EC27DQ34213765-5CC047B4-B84A-4234-91D7-4D24E1693CC8Q34568677-F7CD220B-BB64-42FF-B80A-B18058DF39B2Q35003647-FFCA244D-B7AE-4ECA-AD65-7FC2DEC5E125Q35052932-41E952A6-C444-49E5-9281-29C5BC08B5B0Q36153245-E4B108A4-A216-4232-9752-450AB912100DQ36192115-42AFF20E-E683-4D03-B303-0134917185C5Q36411622-1FE9069B-6779-4146-BC75-057252744FDBQ36534195-69EEEEAC-4574-4FA7-9F5F-4D19373ADBD8Q37046852-915B7CF4-0A4D-424D-B457-979E55429D6BQ37317462-7F6EB2FD-4CEF-428F-BCA5-60BF1C2DE9A1Q37595952-2824F521-2601-41B0-8A8A-28C804B4E670Q37637994-A18526F9-A377-4426-B799-AC69036733E1Q37687133-E3B4C38A-45F5-4B4A-810E-7FD7F07372CEQ38163522-AA9B2526-18A4-4883-8CDE-ECEFC83653E0Q38197831-F1353083-AFFA-43B6-A843-D3263F6AFFA8Q38850372-B15A784C-2270-4F59-AEE3-7EEE544E8794Q38857159-3D6AF23C-BF6C-4FC8-8522-882E9E1F5616Q39319331-65968DB9-B99E-4F7F-8740-8EE96FF49FF1Q42376378-2B423A1C-2261-48EC-8097-B4BD03F36AFAQ42718504-1712D633-51D5-4206-AEC0-F9DCDF0E423CQ47098139-289A5A6B-870D-45C2-A01A-BE4CF1B3D8F8Q47158378-E8FEDE37-904C-4B79-8709-A1BFD96CA6C1Q48874506-C9A8096F-5C71-4036-B4DC-0487EA9138EBQ49335206-9E376D74-6CE2-4FE8-B7C3-471C81D91DA5Q57483228-2AA52BAD-4BF2-402D-ABB7-D03D85FFB361
P2860
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evolving strategies for the tr ...... -tailored therapeutic options.
@en
Evolving strategies for the tr ...... -tailored therapeutic options.
@nl
type
label
Evolving strategies for the tr ...... -tailored therapeutic options.
@en
Evolving strategies for the tr ...... -tailored therapeutic options.
@nl
prefLabel
Evolving strategies for the tr ...... -tailored therapeutic options.
@en
Evolving strategies for the tr ...... -tailored therapeutic options.
@nl
P50
P1476
Evolving strategies for the tr ...... y-tailored therapeutic options
@en
P2093
Marzia Di Pietro Paolo
Michela Del Prete
P304
P356
10.1016/J.CTRV.2010.08.001
P577
2010-08-25T00:00:00Z